Showing 7481-7490 of 8692 results for "".
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl
- Analysis: DSP Gene Variants in PPK Linked to Cardiomyopathy Riskhttps://practicaldermatology.com/news/analysis-dsp-gene-variants-ppk-linked-cardiomyopathy-risk/2468747/A Danish cohort study suggests genetic testing is crucial in accurately diagnosing and subclassifying palmoplantar keratoderma (PPK), a condition
- Upadacitinib Effective in Adolescents With AD Through 76 Weekshttps://practicaldermatology.com/news/upadacitinib-effective-adolescents-ad-through-76-weeks/2468724/Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology. “Upadacitinib in Adolescents With Moderate to Sev
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- FDA Greenlights BIMZELX for Chronic Hidradenitis Suppurativahttps://practicaldermatology.com/news/fda-greenlights-bimzelx-chronic-hidradenitis-suppurativa/2468635/The Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for adults with moderate-to-severe hidradenitis suppurativa (HS), making it the first treatment to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F). According to a press release f
- Acne Insights: Strategies and Solutions at 2024 SDPA Fallhttps://practicaldermatology.com/news/acne-insights-strategies-and-solutions-2024-sdpa-fall/2468634/The SDPA’s 22nd Annual Fall Dermatology Conference was held last week at the Fontainebleau in Las Vegas. Conference Medical Director Hilary Baldwin, MD, joined Shanna Miranti, MPAS, PA-C, in a discussion called “Acne Insights: Expert Strategies and Solutions from the Pros.” The presentatio
- Analyses: Ruxolitinib Cream Reduces AD Symptom Burden in 12 Hourshttps://practicaldermatology.com/news/analyses-ruxolitinib-cream-reduces-ad-symptom-burden-12-hours/2468615/Ruxolitinib cream significantly reduced skin pain and improved patient-reported outcomes (PROs) in individuals with mild-to-moderate atopic dermatitis (AD), with improvements sustained over 52 weeks, according to data from the TRuE-AD1 and TRuE-AD2 studies. Researchers the results publishi
- Zasocitinib Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/study-zasocitinib-effective-moderate-severe-psoriasis/2468601/Results from a recent placebo-controlled trial of zasocitinib showed promise in improving skin clearance for patients with moderate to severe plaque psoriasis. The phase 2b study, conducted across multiple centers in the United States and Canada, included 259 patients treated over 12 week